Literature DB >> 17911641

Hematin promotes complement alternative pathway-mediated deposition of C3 activation fragments on human erythrocytes: potential implications for the pathogenesis of anemia in malaria.

Andrew W Pawluczkowycz1, Margaret A Lindorfer, John N Waitumbi, Ronald P Taylor.   

Abstract

Childhood malaria caused by Plasmodium falciparum is often characterized by severe anemia at low parasite burdens; the mechanism(s) responsible for this pathology remain to be defined. We have reported, based on clinical observations and in vitro models, that complement control proteins on erythrocytes such as CR1, the immune adherence receptor specific for C3b, may be reduced in childhood malaria, suggesting a possible role for complement in erythrocyte destruction. Intravascular lysis of iE by P. falciparum leads to release of erythrocyte breakdown products such as hemoglobin and hematin, which have inflammatory properties. In the present article, we demonstrate that in serum and in anticoagulated whole blood, moderate concentrations of hematin activate the alternative pathway of complement and promote deposition of C3 activation and breakdown products on erythrocytes. The degree of C3 fragment deposition is directly correlated with erythrocyte CR1 levels, and erythrocytes opsonized with large amounts of C3dg form rosettes with Raji cells, which express CR2, the C3dg receptor which is expressed on several types of B cells in the spleen. Thus, the reaction mediated by hematin promotes opsonization and possible clearance of the youngest (highest CR1) erythrocytes. A mAb specific for C3b, previously demonstrated to inhibit the alternative pathway of complement, completely blocks the C3 fragment deposition reaction. Use of this mAb in nonhuman primate models of malaria may provide insight into mechanisms of erythrocyte destruction and thus aid in the development of targeted therapies based on inhibiting the alternative pathway of complement.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17911641     DOI: 10.4049/jimmunol.179.8.5543

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  Critical role of C5a in sickle cell disease.

Authors:  Gregory M Vercellotti; Agustin P Dalmasso; Terry R Schaid; Julia Nguyen; Chunsheng Chen; Marna E Ericson; Fuad Abdulla; Trevor Killeen; Margaret A Lindorfer; Ronald P Taylor; John D Belcher
Journal:  Am J Hematol       Date:  2019-01-03       Impact factor: 10.047

2.  P-selectin drives complement attack on endothelium during intravascular hemolysis in TLR-4/heme-dependent manner.

Authors:  Nicolas S Merle; Romain Paule; Juliette Leon; Marie Daugan; Tania Robe-Rybkine; Victoria Poillerat; Carine Torset; Véronique Frémeaux-Bacchi; Jordan D Dimitrov; Lubka T Roumenina
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-08       Impact factor: 11.205

3.  Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles.

Authors:  Nicolas S Merle; Anne Grunenwald; Helena Rajaratnam; Viviane Gnemmi; Marie Frimat; Marie-Lucile Figueres; Samantha Knockaert; Sanah Bouzekri; Dominique Charue; Remi Noe; Tania Robe-Rybkine; Marie Le-Hoang; Nathan Brinkman; Thomas Gentinetta; Monika Edler; Sara Petrillo; Emanuela Tolosano; Sylvia Miescher; Sylvain Le Jeune; Pascal Houillier; Sophie Chauvet; Marion Rabant; Jordan D Dimitrov; Veronique Fremeaux-Bacchi; Olivier P Blanc-Brude; Lubka T Roumenina
Journal:  JCI Insight       Date:  2018-06-21

4.  Complement Component C5 and TLR Molecule CD14 Mediate Heme-Induced Thromboinflammation in Human Blood.

Authors:  Anub M Thomas; Alexandra Gerogianni; Martin B McAdam; Yngvar Fløisand; Corinna Lau; Terje Espevik; Per H Nilsson; Tom Eirik Mollnes; Andreas Barratt-Due
Journal:  J Immunol       Date:  2019-08-14       Impact factor: 5.422

5.  Heme interacts with c1q and inhibits the classical complement pathway.

Authors:  Lubka T Roumenina; Maria Radanova; Boris P Atanasov; Krastio T Popov; Srinivas V Kaveri; Sébastien Lacroix-Desmazes; Véronique Frémeaux-Bacchi; Jordan D Dimitrov
Journal:  J Biol Chem       Date:  2011-03-22       Impact factor: 5.157

6.  Deletion of the complement phagocytic receptors CR3 and CR4 does not alter susceptibility to experimental cerebral malaria.

Authors:  T N Ramos; D C Bullard; S R Barnum
Journal:  Parasite Immunol       Date:  2012-11       Impact factor: 2.280

7.  Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia.

Authors:  Margaret A Lindorfer; Erika M Cook; Edimara S Reis; Daniel Ricklin; Antonio M Risitano; John D Lambris; Ronald P Taylor
Journal:  Clin Immunol       Date:  2016-08-18       Impact factor: 3.969

8.  Plasmodium coatneyi in rhesus macaques replicates the multisystemic dysfunction of severe malaria in humans.

Authors:  Alberto Moreno; Monica Cabrera-Mora; Anapatricia Garcia; Jack Orkin; Elizabeth Strobert; John W Barnwell; Mary R Galinski
Journal:  Infect Immun       Date:  2013-03-18       Impact factor: 3.441

Review 9.  Complement inhibitors to treat IgM-mediated autoimmune hemolysis.

Authors:  Diana Wouters; Sacha Zeerleder
Journal:  Haematologica       Date:  2015-11       Impact factor: 9.941

Review 10.  Mechanisms of haemolysis-induced kidney injury.

Authors:  Kristof Van Avondt; Erfan Nur; Sacha Zeerleder
Journal:  Nat Rev Nephrol       Date:  2019-08-27       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.